Innovative Cancer Drug Shows Promise in Treating Pulmonary Fibrosis

Wed 23rd Apr, 2025

Researchers at Tulane University have discovered a potential breakthrough in treating idiopathic pulmonary fibrosis (IPF), a serious lung condition that currently affects over 3 million individuals globally and has no known cure.

IPF is characterized by progressive lung scarring, leading to severe breathing difficulties. Alarmingly, around half of those diagnosed with the disease do not survive beyond three years, as existing treatments only manage to slow its progression rather than halt or reverse it.

In a recent publication in the Journal of Clinical Investigation, scientists from Tulane University revealed that an FDA-approved cancer medication could stimulate the immune system to eliminate damaged cells responsible for lung scarring, potentially restoring lung function in IPF patients.

In healthy lungs, fibroblasts play a vital role in tissue repair. However, in individuals suffering from IPF, certain fibroblasts and adjacent epithelial cells malfunction, becoming "senescent." These cells fail to divide or die as intended, leading to their accumulation and the resultant stiffening and scarring of lung tissue.

The research team identified that the build-up of these senescent cells is partly due to a protein known as CTLA4, which inhibits immune activity. By utilizing ipilimumab, an immunotherapy drug already used for cancer treatment, the researchers were able to block CTLA4 in experimental mice. This action effectively lifted the inhibition on specific immune cells called T cells, allowing them to target and eliminate the senescent fibroblasts. Consequently, the treated mice exhibited notable improvements in lung tissue regeneration and a reduction in scarring.

According to the senior researcher, the CTLA4 protein functions to prevent excessive inflammation by regulating T cell activity. However, an overabundance of this regulatory protein can hinder beneficial inflammation necessary for eliminating senescent cells. The focus of this research is to inhibit the inhibitory effects of CTLA4 to restore the immune response.

Through analysis of both human and mouse IPF lung tissues, the team found elevated levels of CTLA4 on T cells in areas with significant scarring. The results indicated that mice receiving ipilimumab displayed enhanced lung repair capabilities and a quicker recovery compared to those who did not receive the treatment.

Lead researcher Santu Yadav emphasized that this research opens up new avenues for IPF treatment. Instead of relying on drugs that destroy senescent cells, the goal is to reactivate the body's immune system to clear these cells naturally.

Further investigation is necessary to assess the effectiveness of therapies targeting CTLA4 and other similar proteins that may rejuvenate the immune system. A critical challenge lies in establishing a safe dosage that enables the immune system to attack senescent cells without triggering harmful inflammation.

Since IPF predominantly affects older adults and is seldom diagnosed in those younger than 50, these findings may also offer hope for treating other age-related conditions. Should this immune-enhancing strategy prove effective in IPF, it could potentially extend to other diseases such as Alzheimer's or cardiovascular issues, where senescent cells are known to accumulate.

The ongoing research aims to determine whether the right pharmacological approach can activate T cells effectively, thereby clearing senescent cells while minimizing adverse effects. Success in this area could bring us closer to addressing numerous age-related conditions and possibly even the aging process itself.


More Quick Read Articles »